Dogwood Therapeutics, Inc. Interest Income (Expense), Net
Dogwood Therapeutics, Inc. (DWTX) reported Interest Income (Expense), Net of $22.77 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2024-05-10
- Dogwood Therapeutics, Inc. interest income (expense), net for the quarter ending 2024-03-31 was $22.77K, a 43.68% decline year-over-year.
- Dogwood Therapeutics, Inc. interest income (expense), net for the quarter ending 2023-12-31 was $34.95K, a 22.60% decline year-over-year.
- Dogwood Therapeutics, Inc. interest income (expense), net for the quarter ending 2023-09-30 was $39.22K, a 136.16% increase year-over-year.
- Dogwood Therapeutics, Inc. interest income (expense), net for the quarter ending 2023-06-30 was $36.31K, a 655.89% increase year-over-year.
- Dogwood Therapeutics, Inc. interest income (expense), net for fiscal 2023 was $150.90K, a 123.64% increase from fiscal 2022.
- Dogwood Therapeutics, Inc. interest income (expense), net for fiscal 2022 was $67.47K, a 1089.62% increase from fiscal 2021.
- Dogwood Therapeutics, Inc. interest income (expense), net for fiscal 2021 was $5.67K.
- Dogwood Therapeutics, Inc. interest income (expense), net for fiscal 2020 was -$384.22K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2024-03-31 | $22.77K 10-Q · filed 2024-05-10 | $57.72K derived: sum of 2 quarters · filed 2024-05-10 | $96.93K derived: sum of 3 quarters · filed 2024-05-10 | $133.25K derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-12-31 | $34.95K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | $74.17K derived: sum of 2 quarters · filed 2024-03-08 | $110.48K derived: sum of 3 quarters · filed 2024-03-08 | $150.90K 10-K/A · filed 2024-03-08 |
| 2023-09-30 | $39.22K 10-Q · filed 2023-11-13 | $75.53K derived: sum of 2 quarters · filed 2023-11-13 | $115.95K 10-Q · filed 2023-11-13 | $161.11K derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-06-30 | $36.31K 10-Q · filed 2023-08-11 | $76.74K 10-Q · filed 2023-08-11 | $121.90K derived: sum of 3 quarters · filed 2024-05-10 | $138.50K derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-03-31 | $40.42K 10-Q · filed 2024-05-10 | $85.58K derived: sum of 2 quarters · filed 2024-05-10 | $102.19K derived: sum of 3 quarters · filed 2024-05-10 | $106.99K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $45.16K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | $61.77K derived: sum of 2 quarters · filed 2024-03-08 | $66.57K derived: sum of 3 quarters · filed 2024-03-08 | $67.47K 10-K/A · filed 2024-03-08 |
| 2022-09-30 | $16.61K 10-Q · filed 2023-11-13 | $21.41K derived: sum of 2 quarters · filed 2023-11-13 | $22.32K 10-Q · filed 2023-11-13 | $23.58K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $4.80K 10-Q · filed 2023-08-11 | $5.71K 10-Q · filed 2023-08-11 | $6.98K derived: sum of 3 quarters · filed 2023-08-11 | $8.49K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $906.00 10-Q · filed 2023-05-12 | $2.17K derived: sum of 2 quarters · filed 2023-05-12 | $3.68K derived: sum of 3 quarters · filed 2023-05-12 | $5.18K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.27K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.78K derived: sum of 2 quarters · filed 2023-03-14 | $4.27K derived: sum of 3 quarters · filed 2023-03-14 | $5.67K 10-K · filed 2023-03-14 |
| 2021-09-30 | $1.51K 10-Q · filed 2022-11-14 | $3.00K derived: sum of 2 quarters · filed 2022-11-14 | $4.41K 10-Q · filed 2022-11-14 | -$75.17K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.50K 10-Q · filed 2022-08-12 | $2.90K 10-Q · filed 2022-08-12 | -$76.68K derived: sum of 3 quarters · filed 2022-08-12 | -$181.12K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.40K 10-Q · filed 2022-05-13 | -$78.18K derived: sum of 2 quarters · filed 2022-05-13 | -$182.62K derived: sum of 3 quarters · filed 2022-05-13 | -$298.82K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$79.58K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$184.02K derived: sum of 2 quarters · filed 2022-03-18 | -$300.22K derived: sum of 3 quarters · filed 2022-03-18 | -$384.22K 10-K · filed 2022-03-18 |
| 2020-09-30 | -$104.44K 10-Q · filed 2021-11-12 | -$220.65K derived: sum of 2 quarters · filed 2021-11-12 | -$304.65K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$116.20K 10-Q · filed 2021-08-13 | -$200.21K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$84.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |